Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Hannah Walker

5 papers in the library · 52 citations · publishing 2020-2024

Papers

The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers

Journal of Psychopharmacology August 5, 2020 Will Lawn, J. P. Hill, Chandni Hindocha et al. 23 citations

A single 600 mg oral dose of cannabidiol did not alter brain activity related to anticipating or receiving rewards in healthy adults. Using functional magnetic resonance imaging during a monetary incentive delay task, the expected reward-related brain regions—including the insula, caudate, nucleus accumbens, anterior cingulate, and orbitofrontal cortex—were activated, but no difference was observed between cannabidiol and placebo. Bayesian analyses confirmed that activity in these regions was similar under both conditions, and behavioral measures of motivation for reward also showed no significant difference. The findings suggest that acute cannabidiol does not affect the neural correlates of reward anticipation or feedback in healthy individuals.

Individual and combined effects of cannabidiol and Δ 9 -tetrahydrocannabinol on striato-cortical connectivity in the human brain

Journal of Psychopharmacology May 20, 2022 Matthew B. Wall, Tom P. Freeman, Chandni Hindocha et al. 21 citations

THC strongly disrupts connectivity between the striatum and cortex, but co-administering CBD mitigates this effect in the limbic striatum network. In one study, inhaled cannabis with 8 mg THC or 8 mg THC plus 10 mg CBD disrupted associative and sensorimotor networks, while THC alone also disrupted the limbic striatum network. In a second study, oral 600 mg CBD increased connectivity in the associative network and caused minor disruptions in limbic and sensorimotor networks. The insula emerges as a key region affected by cannabinoid-induced changes in functional connectivity, with implications for understanding cannabis-related disorders and developing cannabinoid therapeutics.

Individual and combined effects of Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) on striato-cortical connectivity in the human brain

bioRxiv (Cold Spring Harbor Laboratory) November 21, 2020 Matthew B. Wall, Tom P. Freeman, Chandni Hindocha et al. 4 citations preprint

Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are two major cannabis constituents with contrasting actions: THC is psychoactive and addiction-promoting, while CBD may have opposite effects. In two placebo-controlled, double-blind studies, inhaled THC (8 mg) strongly disrupted functional connectivity in associative and sensorimotor striatal networks, and this disruption was selectively alleviated in the limbic striatum when co-administered with CBD (10 mg). Oral CBD (600 mg) alone increased connectivity in the associative network but caused minor decreases in limbic and sensorimotor networks. The insula emerged as a key region affected by cannabinoid-induced connectivity changes, with implications for cannabis-related disorders and cannabinoid therapeutics.

Transient peripheral blood transcriptomic response to ketamine treatment in children with ADNP syndrome.

Translational Psychiatry July 25, 2024 Ariela S. Buxbaum Grice, Laura Sloofman, Tess Levy et al. 3 citations

A single low-dose intravenous ketamine infusion (0.5 mg/kg) triggers immediate and profound changes in gene expression in the blood of individuals with ADNP syndrome, a rare neurodevelopmental disorder. These alterations include upregulation of immune and inflammatory processes and downregulation of RNA processing and metabolism, with specific enrichment in monocyte-related expression patterns. The changes are transient, returning to baseline within 24 hours to one week. The findings clarify ketamine's molecular effects and support further research into its therapeutic targets for ADNP syndrome and potentially autism spectrum disorder.

Transient peripheral blood transcriptomic response to ketamine treatment in children with ADNP syndrome

medRxiv Preprint Server January 29, 2024 Ariela S. Buxbaum Grice, Laura Sloofman, Tess Levy et al. 1 citation preprint

A single low-dose intravenous ketamine infusion (0.5 mg/kg) triggers immediate and profound changes in gene expression in the blood of 10 individuals with ADNP syndrome, a rare neurodevelopmental disorder causing intellectual disability, developmental delay, and autism spectrum disorder. The alterations are enriched in monocyte-related patterns, with up-regulation of immune and inflammatory processes and down-regulation of RNA processing and metabolism. These changes are transient, returning to baseline within 24 hours to one week after treatment. The findings clarify ketamine's molecular effects and may guide therapeutic development for ADNP syndrome and possibly autism spectrum disorder.